Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia
- PMID: 19934211
- PMCID: PMC2833123
- DOI: 10.1093/schbul/sbp125
Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia
Abstract
Negative symptoms encompass diminution in emotional expression and motivation, some of which relate to human attributes that may not be accessible readily in animals. Additionally, their refractoriness to treatment precludes therapeutic validation of putative models. This review considers critically the application of mutant mouse models to the study of the pathobiology of negative symptoms. It focuses on 4 main approaches: genes related to the pathobiology of schizophrenia, genes associated with risk for schizophrenia, neurodevelopmental-synaptic genes, and variant approaches from other areas of neurobiology. Despite rapid advances over the past several years, it is clear that we continue to face substantive challenges in applying mutant models to better understand the pathobiology of negative symptoms: the majority of evidence relates to impairments in social behavior, with only limited data relating to anhedonia and negligible data concerning avolition and other features; even for the most widely examined feature, social behavior, studies have used diverse assessments thereof; modelling must proceed in cognizance of increasing evidence that genes and pathobiologies implicated in schizophrenia overlap with other psychotic disorders, particularly bipolar disorder. Despite the caveats and challenges, several mutant lines evidence a phenotype for at least one index of social behavior. Though this may suggest superficially some shared relationship to negative symptoms, it is not yet possible to specify either the scope or the pathobiology of that relationship for any given gene. The breadth and depth of ongoing studies in mutants hold the prospect of addressing these shortcomings.
Similar articles
-
Mutant mouse models: phenotypic relationships to domains of psychopathology and pathobiology in schizophrenia.Schizophr Bull. 2010 Mar;36(2):243-5. doi: 10.1093/schbul/sbq004. Epub 2010 Feb 12. Schizophr Bull. 2010. PMID: 20154202 Free PMC article. Review.
-
Genetically modified mice related to schizophrenia and other psychoses: seeking phenotypic insights into the pathobiology and treatment of negative symptoms.Eur Neuropsychopharmacol. 2014 May;24(5):800-21. doi: 10.1016/j.euroneuro.2013.08.009. Epub 2013 Oct 12. Eur Neuropsychopharmacol. 2014. PMID: 24290531 Review.
-
Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.Schizophr Bull. 2010 Mar;36(2):246-70. doi: 10.1093/schbul/sbp132. Epub 2009 Nov 9. Schizophr Bull. 2010. PMID: 19900963 Free PMC article. Review.
-
Behavioral phenotypes for negative symptoms in animal models of schizophrenia.J Pharmacol Sci. 2014;126(4):310-20. doi: 10.1254/jphs.14R02CR. Epub 2014 Nov 18. J Pharmacol Sci. 2014. PMID: 25409784 Review.
-
Advancing a functional genomics for schizophrenia: psychopathological and cognitive phenotypes in mutants with gene disruption.Brain Res Bull. 2010 Sep 30;83(3-4):162-76. doi: 10.1016/j.brainresbull.2009.09.010. Epub 2009 Oct 1. Brain Res Bull. 2010. PMID: 19800398 Review.
Cited by
-
Neural mechanisms underlying stress resilience in Ahi1 knockout mice: relevance to neuropsychiatric disorders.Mol Psychiatry. 2014 Feb;19(2):243-52. doi: 10.1038/mp.2013.123. Epub 2013 Sep 17. Mol Psychiatry. 2014. PMID: 24042478
-
Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia.Transl Psychiatry. 2013 Jan 22;3(1):e221. doi: 10.1038/tp.2012.149. Transl Psychiatry. 2013. PMID: 23340504 Free PMC article.
-
Increased expression of receptor phosphotyrosine phosphatase-β/ζ is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes.Transl Psychiatry. 2011 May 10;1(5):e8. doi: 10.1038/tp.2011.8. Transl Psychiatry. 2011. PMID: 22832403 Free PMC article.
-
The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.Schizophr Bull. 2010 Nov;36(6):1066-72. doi: 10.1093/schbul/sbq106. Epub 2010 Sep 24. Schizophr Bull. 2010. PMID: 20870929 Free PMC article. Review.
-
Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures.Schizophr Bull. 2014 Nov;40(6):1328-37. doi: 10.1093/schbul/sbu026. Epub 2014 Mar 22. Schizophr Bull. 2014. PMID: 24657876 Free PMC article.
References
-
- Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand. 2007;115:4–11. - PubMed
-
- Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia “just the facts” 4. Clinical features and conceptualization. Schizophr Res. 2009;110:1–23. - PubMed
-
- Ellenbroek BA, Cools AR. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol. 2000;11:223–233. - PubMed
-
- Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology. 2000;23:223–239. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous